Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-03-30 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2022年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a special explanation regarding non-operating fund occupation and other related party fund transactions for the year 2022 by Shenzhen BGI Genomics Co., Ltd. It references an audit report issued by Ernst & Young Hua Ming CPA Firm on March 29, 2023, for the 2022 financial statements. The document includes detailed tables summarizing related party transactions and fund movements, with accounting details and notes. It is a standalone report focusing on audit-related information about specific financial transactions and compliance with regulatory guidelines on related party funds, rather than a full annual report or interim financial report. It is not a general annual report (10-K), nor a management discussion, nor a simple announcement. The presence of an audit opinion reference and detailed reconciliation with audited financial statements indicates it is an Audit Report / Information type document, specifically a special audit explanation on related party funds. The document length (9504 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2022
2023-03-30 Chinese
2022年度环境、社会及公司治理（ESG）报告
Regulatory Filings
2023-03-30 Chinese
关于召开2022年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2022 Annual General Meeting (AGM) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, and instructions for shareholders to attend and vote. The document does not contain the actual annual report or financial statements but rather the notification and procedural details for the AGM. The presence of agenda items such as the 2022 annual report and financial budget proposals indicates it is related to the AGM. The document length is about 5610 characters, which is consistent with a detailed meeting notice rather than a full annual report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-03-30 Chinese
2022年度独立董事述职报告（曹亚）
Board/Management Information Classification · 95% confidence The document is titled '2022年度独立董事述职报告' which translates to '2022 Annual Independent Director's Work Report' for Shenzhen BGI Genomics Co., Ltd. It details the independent director's attendance at board meetings, opinions on various board resolutions, committee work, investigations, investor protection efforts, and training during the 2022 fiscal year. The content focuses on the independent director's duties and oversight activities rather than financial results or audit opinions. It is a detailed report on board/management activities and governance oversight rather than a financial report or audit report. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (5485 characters) and detailed content confirm it is a full report, not a brief announcement or certification.
2023-03-30 Chinese
2022年年度财务报告
Annual Report Classification · 100% confidence The document is titled "深圳华大基因股份有限公司 2022 年年度财务报告" which translates to "Shenzhen BGI Genomics Co., Ltd. 2022 Annual Financial Report." It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and changes in equity for the fiscal year ending December 31, 2022. The length of the document is substantial (15,000 characters), and it includes comprehensive financial data and analysis for the full fiscal year 2022. This matches the definition of an Annual Report (10-K), which is an official yearly report covering company activity and full financial performance. There is no indication that this is merely an announcement or a certification, and the content is not limited to interim or quarterly data. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-03-30 Chinese
2022年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by Shenzhen BGI Genomics Co., Ltd. in 2022. It includes specifics about the amount raised, allocation, investment projects, use of idle funds, and compliance with regulatory guidelines. The content focuses on the management and actual use of capital raised through a specific stock issuance, with detailed tables and explanations of fund deployment and project progress. This matches the description of a Capital/Financing Update, which covers updates on company fundraising and capital structure changes. The document is lengthy (over 12,000 characters) and contains substantive financial and operational data related to the raised capital, not just an announcement or summary. Therefore, it is classified as a Capital/Financing Update (CAP).
2023-03-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.